Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
PAREXEL announced a group of initiatives that include a re-designed corporate website, a global marketing and advertising campaign and the rebranding of its technology subsidiary Perceptive Informatics to PAREXEL informatics.
According to the company's press release, the PAREXEL Informatics branding is in response to sponsors seeking multiple solutions from a single service provider. Said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL in that release, "We are more closely integrating our clinical research and technology offerings to meet this need. Toward that end, the new PAREXEL Informatics branding communicates our commitment to providing technology-driven solutions that complement our other clinical trial services, without changing our overall go-to-market strategy."
PAREXEL will maintain the Perceptive brands to identify specific PAREXEL Informatics offerings that have market recognition that has been built over the years. These include Perceptive MyTrials eClinical platform, the Perceptive Partner Program and the Perceptive Institute.
Read the full release here.